Anzeige
Mehr »
Login
Donnerstag, 05.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 02.02.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
02.02.Konecranes Oyj: Konecranes Plc's Financial statement release 2023: All-time high sales and comparable EBITA margin in 202350KONECRANES PLC FINANCIAL STATEMENT RELEASE 2023 FEBRUARY 2, 2024 8:30 am EETKonecranes Plc's Financial statement release 2023: All-time high sales and comparable EBITA margin in 2023All-time high sales...
► Artikel lesen
02.02.Consti Oyj: Consti Plc Financial Statements Bulletin for January - December 20231322.2.2024 08:30:02 EET | Consti Oyj | Financial Statement Release CONSTI PLC FINANCIAL STATEMENTS BULLETIN 2 FEBRUARY 2024, at 8.30 a.m. Consti Plc Financial Statements Bulletin...
► Artikel lesen
02.02.Rejlers AB: Year-end report Rejlers AB January - December 202388October - December Net sales increased by 14.4% to SEK 1,132.6 million (990.2) Organic sales growth amounted to 3.2% (8.6) EBITA amounted to SEK 90.5 million (91.8), and the EBITA margin was 8.0%...
► Artikel lesen
02.02.Trelleborg AB: Interim report and year-end report 2023 130A solid end to the year"2023 was Trelleborg's best year to date, with the Group reporting its highest sales and earnings on record. During the year, we transformed and improved Trelleborg in a number...
► Artikel lesen
02.02.Lifco AB: Year-end report 2023152Reporting period January - DecemberNet sales increased 13.5 per cent to SEK 24,454 (21,552) million. Organic growth amounted to 0.0 per cent.EBITA increased 21.5 per cent to SEK 5,664 (4,662) million.The...
► Artikel lesen
02.02.Nanologica AB: Year-End Report 2023386FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to TSEK 75 (674) and for the full year to TSEK 1,443 (1,555) • The operating loss for the quarter amounted to TSEK -35,638 (-13,251) and...
► Artikel lesen
02.02.Addnode Group AB: Year-End Report 1 January - 31 December 2023280GROWTH COMBINED WITH STABLE EARNINGS AND CASH FLOW"In 2023, we have continued to invest in new companies, software and employees. In addition we have implementedefficiency measures and merged operations...
► Artikel lesen
02.02.AddLife AB: Year-end report 1 January - 31 December 2023316Strong cash flow and significant actions to improve profitability within Medtech "Demand is healthy in the markets and segments where AddLife's companies operate. We can now summarize 2023 as a...
► Artikel lesen
02.02.Lakeshore Acquisition II Corp. Announces Effectiveness of Registration Statement and Date for General Meeting to Approve Proposed Business Combination with Nature's Miracle180Extraordinary General Meeting Scheduled for February 15, 2024 Stockholders of Record as of January 10, 2024 are Eligible to Vote at the Meeting NEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Lakeshore...
► Artikel lesen
02.02.TomTom delivers growth and strong cash flow in 2023251TOMTOM'S CHIEF EXECUTIVE OFFICER, HAROLD GODDIJN "We made good progress toward our goals in 2023, delivering revenue growth in Location Technology, improving our profitability, and bringing our new...
► Artikel lesen
02.02.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)243SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
02.02.Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)563BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
► Artikel lesen
02.02.Hanna Capital Corp.: Hanna Announces Transfer of Listing to NEX512TORONTO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Hanna Capital Corp. (the "Corporation") (TSX Venture Exchange: HCC) (Frankfurt: 04U1) announces that it has been advised by the TSX Venture Exchange that...
► Artikel lesen
02.02.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)434SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development...
► Artikel lesen
02.02.MidWestOne Bank: MidWestOne Financial Group, Inc. Completes Acquisition of Denver Bankshares, Inc.348IOWA CITY, Iowa, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) ("MidWestOne" or the "Company"), parent company of MidWestOne Bank (the "Bank"), today announced...
► Artikel lesen
02.02.Axogen, Inc.: Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)410ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries...
► Artikel lesen
02.02.Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)429CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the Compensation...
► Artikel lesen
02.02.Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)601SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...
► Artikel lesen
02.02.Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)378BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
► Artikel lesen
02.02.Bit Brother Ltd.: Bit Brother Limited Receives Notice of Delisting from Nasdaq1.222CHANGSHA, China, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Bit Brother Limited ("Bit Brother, " "We" or the "Company") (Nasdaq: BETS), today announced that it has received a notice (the "Notice") from the...
► Artikel lesen
Seite:  Weiter >>